HGH vs TB-500 (Ac-LKKTETQ)
FDA Approved vs Moderate Research
synergistic Mechanism-based · 47% HGH and TB-500 (Ac-LKKTETQ) work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
HGH TB-500 (Ac-LKKTETQ)
Weight 22,124 Da 844 Da
Half-life 3-4 hours (SC), 20-30 minutes (IV) Not precisely established; effects persist longer than 24 hours
Chain 191 amino acids 7 amino acids
Type Single-chain polypeptide with two disulfide bridges Acetylated heptapeptide
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
TB-500 (Ac-LKKTETQ)
01 Promotes wound healing
02 Enhances cell migration
03 Supports angiogenesis (new blood vessel formation)
04 Reduces inflammation
05 Promotes keratinocyte migration
06 Supports collagen deposition
07 Enhances tissue repair
08 Active region of thymosin beta-4
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
TB-500 (Ac-LKKTETQ)
2-2.5mg per injection / 2x weekly (e.g., Monday and Thursday)
Loading phase 2-2.5 mg 2x weekly for 4-6 weeks
Maintenance 2 mg Weekly or bi-weekly
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
TB-500 (Ac-LKKTETQ)
Injection site reactions
Mild fatigue
Head rush (reported)
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Not authorized for medicinal use
Active cancer (theoretical concern)
Pregnancy or breastfeeding
Prohibited by WADA in sports
Research Evidence
HGH TB-500 (Ac-LKKTETQ)
Status FDA Approved Moderate Research
References 4 studies 4 studies
Latest 2024 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.